Webinar: A 6 segment video by Dr. Guy Weigold sharing best practices for the acquisition of CCTA, image reconstruction, reducing artifacts, post processing techniques and interpretation of the results that lead to accurate clinical interpretation. The webinar also discusses cases that include FFRCT results and the impact of FFRCT in clinical decision making.
Instructions: In order to watch this free webinar, please create a guest account on the SCCT website. Upon completing registration, please click on SCCT Learning Center under the Education tab. The webinar will be available in your Education Library.
A 4 segment video by Dr. Jonathon Leipsic MD, FRCPC, FSCCT summarizing the rationale and best practices for administering nitroglycerin for acquiring CCTA in accordance with the SCCT guidelines. The video also highlights the effect of nitrates administration on the coronary vasculature, and ultimately the CCTA diagnostic accuracy.
Section 1: Effect on Vasculature
Section 2: Nitrate Recommendations
Section 3: Physiologic effects, Dosage and Timing
Section 4: Summary
All of these resources are available to HeartFlow sites and can be customized. Please reach out to a local HeartFlow CT Application Specialist to gain access.
The training provides 2.25 Category A ASRT credit hours. It reviews the current invasive and noninvasive technologies used to assess the coronary artery disease (CAD). The discussions also focus on how the growth of coronary CT angiography (CCTA) are answering patient and clinician questions more effectively than ever before.
Please contact your local HeartFlow Account Manager to schedule and customize a training.
Provides guidelines on administering Beta blockers to improve CCTA acquisition. This poster can be created with site specific guidelines.
Provides instructions and important reminders on CCTA acquisition protocols such as patient preparation, image acquisition, and image reconstruction. This poster can be created with site specific protocols and is intended to be displayed at the CT scanner console.
Reviews evidence on the diagnostic accuracy of CCTA, and the impact of CCTA on patient management and outcomes. CT readers and referring physicians can utilize this tool in their pre-authorization peer to peer discussions with the medical directors of various health plans.
HeartFlow’s field-based Clinical Account and CT Applications Teams help advance the site’s CT capabilities throughout the lifetime of their account. These teams use best practices and several education and teaching methods (including hands-on case reviews and training).
HeartFlow’s implementation team, including CT Applications specialists and Clinical Account Managers, actively work with sites to ensure they can achieve acceptable image quality for HeartFlow Analysis. HeartFlow performs a baseline evaluation of CCTA quality and provides detailed image quality feedback and observations of site’s practices (note: this baseline review is conducted following HeartFlow’s on-site assessment and review training on best practices for CCTA and a review of the SCCT guidelines). Training and educational materials are provided to imaging physicians and radiographers on SCCT cardiac CTA guidance and image specifications for the HeartFlow Analysis. In addition, training on the use of the HeartFlow Analysis is provided to radiologists, radiographers and cardiologists, as well as other support staff.
HeartFlow’s CT Applications team works with customers to ensure imaging quality continues to be sufficient for HeartFlow Analysis. HeartFlow monitors quality and acquisition parameters, and routinely reviews cases and best practices with sites to optimize acceptance rates for HeartFlow Analysis.
In addition to site-specific education, HeartFlow sponsors educational events at large conferences, symposia, etc., and supports physician continuing education. HeartFlow offers education programs for Radiographers and Clinicians alike, including physician-led videos, webinars, peer-to-peer discussions, and instructor-led programs (including some with SOR or category A ASRT Credits).
HeartFlow Analysis is consisted of four main functions; FFRCT, Planner, Roadmap, and Plaque. All four functions are cleared for clinical use in the United States, Bahrain, Israel, and United Arab Emirates. Only FFRCT and Planner functions are cleared cleared for clinical use in Europe, United Kingdom, Australia, Canada, and Japan. Please see HeartFlow Analysis Indications for Use and Instructions for Use for more information.
© 2024 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.